Congenica was founded in 2014 as a Spin out from the Wellcome Sanger Institute, one of the leading genetic research institutions. The company’s platform, Sapientia, is a clinical genomic analytics platform that provides integration of human DNA sequences with deep clinical phenotyping, enabling clinicians and researchers to provide actionable interpretation of genetic disease for patients.

Congenica improves the opportunity for genomic characterization of disease. Supporting laboratories to achieve 30% higher analytical yields than averages and reduce analysis times and costs by 95%. This enables improvement of diagnostic confidence, maximize workflow efficiency and increase diagnostic yield and case throughput. It also supports rapid and accurate diagnoses and disease characterization, helping to provide patients with the treatment they need faster.

In 2019, Congenica signed an agreement with the National Genetic Centre to aid in the management of Omani patients with rare genetic diseases.

Industry: Digital Health Headquarters: UK Year Invested: 2020 Visit Website